From Proof-of-Concept to Patient: Single Cell and Spatial Tools Across the Drug Development Continuum

Where single cell and spatial tools fit across drug development, from de-risking targets to patient stratification.

About the webinar

Single cell and spatial transcriptomics are changing how we understand disease biology and test therapeutic hypotheses.

In this webinar, 10x Genomics will cover technologies implemented at both ends of the pipeline: de-risking targets and mechanisms in proof-of-concept drug development, and generating translational readouts that inform patient stratification and exploratory clinical trial endpoints. We will also preview the next wave of technology, including GEM-X Multiome and VIPerturb-seq, and what these advances mean for researchers building biomarker and mechanism-of-action strategies.

Propath UK will showcase an exploration of tumour heterogeneity and a sample-to-insight pipeline for identifying putative therapeutic targets from 10x Genomics Xenium data. Through a case study comparing primary and metastatic tumours, utilising a custom single cell transcriptomics panel including tertiary lymphoid structure (TLS) and fibroblast signatures, Propath will highlight tumour-cell populations enriched in metastatic lesions. They will explore how the distinct molecular profiles of these populations could reveal mechanisms associated with metastatic progression and potential vulnerabilities for therapeutic intervention in primary disease.

Attendees will leave with a clear view of where these tools fit in their own programmes and how to start applying them.

All times are UK time (GMT).

Please reach out to Will McTavish at [email protected].